Atopic March and Disease Modification

Authors

  • Adam Byrne, MD, M.Sc.

DOI:

https://doi.org/10.58931/cait.2024.4s0160

Abstract

Over generations of health care providers, the approach to medicine has predominantly been reactive in nature, addressing symptoms as they arise. With advancements in medical research that explore the underlying mechanisms of disease, associated comorbidities, and improved therapeutic options, the objectives of medicine are transforming. While managing active symptoms remains crucial, there is a growing focus on altering the future trajectory of a disease which will result in new avenues to improve the quality of life of patients. In this evolving landscape, the atopic march emerges as a promising area for disease modification.

Author Biography

Adam Byrne, MD, M.Sc.

Dr. Adam Byrne is originally from St. John’s, Newfoundland, where he graduated from Memorial University with a M.Sc. in Biochemistry. He worked on several research projects afterwards at Memorial University, including the metabolism of adipose tissue before moving to novel detection of HPV infection at Newfoundland Public Health Labs. He returned to medical school at Memorial University before completing his Pediatrics residency at the University of Ottawa. He completed a fellowship in Pediatric Clinical Immunology and Allergy at McGill University before returning to Ottawa, where he now practices Allergy and Immunology in private practice in the community, as well as at the Children’s Hospital of Eastern Ontario, where he was the recipient of the award for clinical excellence in his first year of practice. Dr. Byrne is a member of various societies, and is a member of the CSACI, where he is active in education as a co-chair of the National Residency Education Program and a member of the Committee for Professional Development.

References

Soller L, Ben-Shoshan M, Harrington DW, Knoll M, Fragapane J, Joseph L, et al. Adjusting for nonresponse bias corrects overestimates of food allergy prevalence. J Allergy Clin Immunol Pract. 2015;3(2):291-293.e292. doi:10.1016/j.jaip.2014.11.006

Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol. 2012;8(1):7. doi:10.1186/1710-1492-8-7

Lynde C, Barber K, Claveau J, Gratton D, Ho V, Krafchik B, et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg. 2005;8 Suppl 5:1-9. doi:10.1007/s10227-005-8080-3

Hill DA, Grundmeier RW, Ramos M, Spergel JM. Eosinophilic Esophagitis is a late manifestation of the allergic march. J Allergy Clin Immunol Pract. 2018;6(5):1528-1533. doi:10.1016/j.jaip.2018.05.010

Alduraywish SA, Standl M, Lodge CJ, Abramson MJ, Allen KJ, Erbas B, et al. Is there a march from early food sensitization to later childhood allergic airway disease? Results from two prospective birth cohort studies. Pediatr Allergy Immunol. 2017;28(1):30-37. doi:10.1111/pai.12651

Ricci G, Patrizi A, Baldi E, Menna G, Tabanelli M, Masi M. Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol. 2006;55(5):765-771. doi:10.1016/j.jaad.2006.04.064

Tran MM, Lefebvre DL, Dharma C, Dai D, Lou WYW, Subbarao P, et al. Predicting the atopic march: results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol. 2018;141(2):601-607.e608. doi:10.1016/j.jaci.2017.08.024

Kijima A, Murota H, AyaTakahashi, Arase N, Yang L, Nishioka M, et al. Prevalence and impact of past history of food afllergy in atopic dermatitis. Allergol Int. 2013;62(1):105-112. doi:10.2332/allergolint.12-OA-0468

Hirota T, Nakayama T, Sato S, Yanagida N, Matsui T, Sugiura S, et al. Association study of childhood food allergy with genome-wide association studies-discovered loci of atopic dermatitis and eosinophilic esophagitis. J Allergy Clin Immunol. 2017;140(6):1713-1716. doi:10.1016/j.jaci.2017.05.034

Yang L, Fu J, Zhou Y. Research progress in atopic march. Front Immunol. 2020;11:1907. doi:10.3389/fimmu.2020.01907

Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131-137. doi:10.1016/j.anai.2017.10.037

Tham EH, Leung DY. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. Allergy Asthma Immunol Res. 2019;11(1):4-15. doi:10.4168/aair.2019.11.1.4

Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803-813. doi:10.1056/NEJMoa1414850

Upton JEM, Correa N, Eiwegger T. Oral immunotherapy for food allergy: what's age got to do with it? Allergy. 2023;78(3):626-628. doi:10.1111/all.15623

Lowe AJ, Su JC, Allen KJ, Abramson MJ, Cranswick N, Robertson CF, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2018;178(1):e19-e21. doi:10.1111/bjd.15747

Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Carlsen KCL, et al. Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database Syst Rev. 2022;11(11):Cd013534. doi:10.1002/14651858.CD013534.pub3

Yamamoto-Hanada K, Kobayashi T, Mikami M, Williams HC, Saito H, Saito-Abe M, et al. Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy. J Allergy Clin Immunol. 2023;152(1):126-135. doi:10.1016/j.jaci.2023.03.008

Alviani C, Roberts G, Mitchell F, Martin J, Zolkipli Z, Michaelis LJ, et al. Primary prevention of asthma in high-risk children using HDM SLIT: assessment at age 6 years. J Allergy Clin Immunol. 2020;145(6):1711-1713. doi:10.1016/j.jaci.2020.01.048

Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73(1):165-177. doi:10.1111/all.13213

Martorano LM, Grayson MH. Respiratory viral infections and atopic development: from possible mechanisms to advances in treatment. Eur J Immunol. 2018;48(3):407-414. doi:10.1002/eji.201747052

Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ, Jr., Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476-1485. doi:10.1016/j.jaci.2015.09.008

Phipatanakul W, Mauger DT, Guilbert TW, Bacharier LB, Durrani S, Jackson DJ, et al. Preventing asthma in high risk kids (PARK) with omalizumab: design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials. 2021;100:106228. doi:10.1016/j.cct.2020.106228

Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293-1300. doi:10.1016/j.jaci.2014.10.013

Matucci-Cerinic C, Viglizzo G, Pastorino C, Corcione A, Prigione I, Bocca P, et al. Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome. Pediatr Allergy Immunol. 2022;33(4):e13770. doi:10.1111/pai.13770

Martinez-Cabriales S, Marcoux D, Liy-Wong C, Prajapati VH, Sibbald C, Cunningham N, et al. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab. Pediatr Dermatol. 2023. doi:10.1111/pde.15418

Martinez-Cabriales S, Marcoux D, Liy-Wong C, Prajapati VH, Sibbald C, Cunningham N, et al. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab. Pediatr Dermatol. 2023. doi:10.1111/pde.15418

Paller AS, Guttman-Yassky E, Irvine AD, Basselga E, de Bruin-Weller M, Jayawardena S, et al. Protocol for a prospective, observational, longitudinal study in pediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design, and methodology. BMJ Open. 2020; 10:e033507

Geba G, Li D, Mohammadi K, Attre R, Ardeleanu M, Musser B. Attenutating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023; 151:757-666

Downloads

Published

2024-01-15

How to Cite

1.
Byrne A. Atopic March and Disease Modification. Can Allergy Immunol Today [Internet]. 2024 Jan. 15 [cited 2024 Nov. 21];4(s01):2–6. Available from: https://canadianallergyandimmunologytoday.com/article/view/4-s01-byrne

Issue

Special Supplement, January 2024

Section

Articles